1CP
ABMD

17 Capital Partners’s Abiomed Inc ABMD Stock Holding History

17 Capital Partners’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$281K Hold
1,145
– – 0.38% 70
2022
Q2 		$283K Hold
1,145
– – 0.36% 77
2022
Q1 		$379K Buy
+1,145
New +$352K 0.4% 73
2021
Q4 		– Sell
-1,170
Closed -$381K – 104
2021
Q3 		$381K Hold
1,170
– – 0.36% 81
2021
Q2 		$365K Buy
+1,170
New +$359K 0.34% 84

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

17 Capital Partners's ABMD Position: Q3 2022 in Review

17 Capital Partners held its Abiomed Inc (ABMD) position steady in Q3 2022 at 1,145 shares worth $281K. The position accounts for 0.38% of the portfolio, ranked #70.

17 Capital Partners first reported a position in ABMD in Q2 2021 and has held it in 5 quarters since. The position peaked at $381K in Q3 2021. 517 funds tracked by Wall St. Rank hold ABMD as of Q3 2022.

  • 17 Capital Partners held 1,145 shares of Abiomed Inc worth $281K as of Q3 2022.
  • 17 Capital Partners left its Abiomed Inc share count unchanged in Q3 2022.
  • Abiomed Inc made up 0.38% of 17 Capital Partners's portfolio in Q3 2022, its #70 holding.
  • 17 Capital Partners first reported a position in Abiomed Inc in Q2 2021 and has held it in 5 quarters since.
  • 17 Capital Partners's Abiomed Inc position peaked at $381K in Q3 2021.
  • 517 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2022.

Based on 17 Capital Partners's 13F filing for Q3 2022, filed 21 Nov 2022.